Lankenau Institute For Medical Research
Wynnewood, PA
- UEI
- X7Y6RNVA4NR6
- CAGE
- 9H779
- Primary NAICS
- Not on record
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Tax Exempt)
- SAM.gov registration date
- Physical address
- 100 East Lancaster Avenue, Wynnewood, PA 19096, USA
- Website
- mainlinehealth.org
- Founded
- 1985
- Employees
- 5K-10K
- Estimated annual revenue
- $1B-$10B
- Industry
-
- Health Care
- Health Care Equipment & Services
- Health Care Providers & Services
- Health Care Services
- SIC code
- 80 Health Services
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Recent federal awards
About Lankenau Institute For Medical Research
Lankenau Institute For Medical Research, a tax-exempt nonprofit research organization based in Wynnewood, Pennsylvania, acts as a prime recipient of federal research grants focused on mechanobiology, immunology, and metabolic disease, with subordinate participation in multi-institutional research collaborations funded by the National Institutes of Health (NIH) and the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).
Lankenau operates exclusively in the federal grant space (93% of recent awards as prime recipient, 7% as sub-recipient) with no federal contract vehicles, IDIQs, or BPAs. The institute's research portfolio centers on translational and basic biomedical science — mechanotransduction mouse models for understanding disease pathogenesis, IDO2 immunomodulation in autoimmune disease, and intracellular pathways driving diabetic complications. Representative prime grants include a September 2025 NIH Office of the Director R21 award for developing mechanotransduction-defective mouse strains (award date September 1, 2025, ultimate completion August 31, 2027), a January 2025 National Institute of Arthritis and Musculoskeletal and Skin Diseases grant (NIAMS) investigating IDO2's cellular and molecular mechanisms in autoimmune disease (ultimate completion December 31, 2029), and a February 2022 NIDDK grant on fructosamine-3-kinase-mediated pathways in diabetic nephropathy (ultimate completion January 31, 2026). In the sub-recipient role, Lankenau participates in inflammatory disease research collaborations under Augusta University Research Institute as the prime grantee, with sub-awards dated July 2025, January 2025, and March 2024 addressing stress myelopoiesis as a therapeutic target.
Customer concentration is heavily weighted toward NIH institutes. The top five grantor agencies account for 83% of recent awards: NIH broadly (17 awards), NIH National Cancer Institute (7 awards), NIDDK (4 awards), the Department of Defense (3 awards), and NIH National Heart Lung and Blood Institute (2 awards). Across 40 awards in the source data spanning 1981 to present, Lankenau has obligated $58.1 million in federal grant funding. Activity has accelerated in 2025 (four awards to date versus one per year in 2020, 2021, 2022, and 2024), though only three awards face ultimate completion inside the next twenty-four months. Lankenau serves twelve distinct federal agencies, with NIH institutes anchoring the portfolio. No federal contract work, GSA Schedule presence, or prime contractor relationships appear in the source data; the institute's federal footprint is exclusively grant-funded basic and translational research in biomedical sciences.
Quick answers
What is Lankenau Institute For Medical Research's UEI?
Lankenau Institute For Medical Research's Unique Entity ID (UEI) in SAM.gov is X7Y6RNVA4NR6.
What is Lankenau Institute For Medical Research's CAGE code?
Lankenau Institute For Medical Research's CAGE code is 9H779.
Where is Lankenau Institute For Medical Research located?
Lankenau Institute For Medical Research's physical address in SAM.gov is 100 East Lancaster Avenue, Wynnewood, PA 19096, USA.
Is Lankenau Institute For Medical Research registered in SAM.gov?
Yes. Lankenau Institute For Medical Research's SAM.gov registration is active through June 26, 2027.
What is Lankenau Institute For Medical Research's most recent federal award?
Lankenau Institute For Medical Research's most recent federal grant award is Defining the cellular and molecular mechanism of IDO2 function driving autoimmune VS.protective immune responses -… (R01AR083882), from National Insititue of Arthritis and Musculoskeletal and Skin Diseases, on January 8, 2025.
On GovTribe
See Lankenau Institute For Medical Research's full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors